Christine E. McLaren

Picture of Christine E. McLaren
Professor, Epidemiology
School of Medicine
Vice Chair for Academic Affairs, Epidemiology
Scientific Member, Genetic Epidemiology Research Institute
Director of Biostatistics, Chao Family Comprehensive Cancer Center
Ph.D., Case Western Reserve University, Biostatistics
M.S., Case Western Reserve University, Mathematical Statistics
M.A., Stanford University, Mathematics Education
B.S., San Jose State University, Mathematics
Phone: (949) 824-4007
Fax: (949) 824-1343
University of California, Irvine
University Research Park
100 Theory, Suite 100
Mail Code: 7555
Irvine, CA 92697
Research Interests
Finite Mixture Distributions, Goodness-of-fit Testing, Statistical Modeling of Biological Processes,Iron Deficiency Anemia, Iron Overload, Hemochromatosis, Epidemiology
Academic Distinctions
Phi Theta Kappa Scholastic Honorary; Stanford University Prospective Teacher Fellowship; Case Western Reserve University Tuition Fellowship; American Statistical Association Presentation Award; American Heart Association Research Fellowship; Visiting Scientific Officer, Wales College of Medicine, U.K.; Fellow, Royal Statistical Society/Institute of Statistics; Senior Honorary Research Fellowship, University of Glasgow, Scotland, U.K.; Phi Kappa Phi Honor Society; Fellow, American Statistical Association; Raybould Visiting Fellowship, University of Queensland, Australia; Senior International Fellowship awarded by the NIH Fogarty International Center; Minnesota College Science Teacher of the Year, Minnesota Academy of Science; Moorhead State University Award for Excellence in Research; University Deans’ Council Nominee for the “1997 U.S. Professors of the Year Program”, Carnegie Foundation for the Advancement of Teaching; American Statistical Association Service Award, Recipient, Faculty Computing Initiative, UC Irvine, Clinical and Translational Science (ICTS) Interdisciplinary Team Science Award 2012, Athena Breast Health Network Program, University of California, Irvine, “Best of ASH” award, given for the 2014 abstract “Exome Sequencing Identifies a GNPAT Variant Associated with Severe Iron Overload in HFE C282Y Homozygous Men with Extreme Phenotypes; Possible Role in Regulation of Hepcidin Expression”, presented at the 56th annual meeting of the American Society of Hematology, San Francisco, CA, December 5-9, 2014, Elected Member, International Statistical Institute 2017, Received Albert Nelson Marquis Lifetime Achievement Award, 2017.
Research Abstract
Statistical models provide insight into the structure of data. Models of biological processes can assist with distinguishing between health and disease. Dr. McLaren's statistical modeling research has concentrated on mixture distribution analysis, goodness-of-fit testing, and hierarchical regression modeling Theof longitudinal data. Medical applications including disease prevalence and estimation of iron overload and hemochromatosis, analysis of distributions of red blood cell volume and hemoglobin concentration in iron deficiency anemia, detection of cisplatin-induced anemia in patients undergoing cancer chemotherapy, and screening for hepatocelluar carcinoma. As a result of her experience with statistical modeling and collaborative medical research, in January of 2000, Dr. McLaren received a $4 million 5-year contract awarded by NIH/NHLBI, "Screening for Iron Overload and Hereditary Hemochromatosis: Field Center". With her oversight, 20,400 primary care patients enrolled in the study at the University of California, Irvine.

Current and Recent Research Projects


Prevalence Estimation: There is now incontrovertible evidence that early diagnosis and therapy of hereditary hemochromatosis prevents virtually all manifestations of the disease and results in normal life expectancy. In contrast, unrecognized and untreated disease leads to cirrhosis, hepatocellular carcinoma and other lethal complications. We analyzed the distribution of transferrin saturation values in the second National Health and Nutrition Examination Survey to estimate the prevalence of hemochromatosis homozygotes and heterozygotes in the United States population. The gene frequencies for hemochromatosis were estimated to be 0.081 for males and 0.070 for females corresponding to prevalences of homozygotes of 6.6 and 4.8 per thousand. Our results confirm that the gene for hemochromatosis is common in the white population of the United States.

Disease Screening: Cost-effectiveness analyses indicate that the cost of screening and treatment for hemochromatosis is far less than the medical cost of treating chronic disabilities resulting from the secondary disease conditions such as cirrhosis and diabetes due to iron overload. In population screening, the number and proportion of individuals identified as having hemochromatosis will depend, in part, upon the specific initial screening criteria applied. Our research efforts have concentrated on identifying appropriate screening values for transferrin saturation to identify hemochromatosis heterozygotes and homozytoges.


Maximum likelihood estimation of finite mixture models using the EM algorithm: Another primary research interest has been in finite mixture distributions and their applications in medicine. After examining the theoretical basis for the statistical evaluation of red blood cell volume distributions we developed a mathematical model of the distribution of the volumes of circulating red cells and verified predictions in healthy individuals and patients with anemia. Analysis of the empirical data required development of a method for log normal parameter estimation appropriate to grouped truncated distributions. We then developed statistical methods for detection of mixtures of two log normal distri-butions in doubly-truncated data when the sample size is large. Alterations in erythrocyte subpopulations were quantified in untransfused patients with refractory anemia, sideroblastic anemia, and patients treated for iron deficiency anemia.

Hierarchical models for screening of iron deficiency anemia: In this joint work with Dr. Padhraic Smyth, UCI Department of Information and Computer Science, we developed a model of the bivariate distribution of hemoglobin concentration and red blood cell volume. A new mixture fitting algorithm was devised to analyze data measured using an automated blood cell analyzer. A two-level classification technique of model parameters achieved accurate discrimination between healthy individuals and patients with disorders of anemia.


Patient-specific Sequential Analysis of Laboratory Data: For this area of concentration, our research group developed statistical methods to sequentially analyze laboratory test results and identify departures from past values. These methods include hierarchical multiple regression modeling, with a weighted minimum risk criteria for model selection, to choose models indicating changes in mean values over time. Clinical applications have included detection of developing iron deficiency anemia, identification of anemia due to cisplatin-based chemotherapy, regulation of T cells numbers in Gaucher disease, and screening for hepatocelluar carcinoma. These methods promise to provide more sensitive techniques for improved diagnostic evaluation of diseases and serial monitoring of response to therapy.
Khan AA; Srivastava R, Chentoufi AA, Kritzer E, Chilukur Si, Garg S, Yu DC, Vahe H, Huang L:, Syed SA, Furness JN, Tran TT, Anthony NB; McLaren CE, Sidney J, Noelle RJ, BenMohamed L. Bolstering the Number and Function of HSV-1-Specific CD8+ TEM and TRM cells in Latently Infected Trigeminal Ganglia Reduces Recurrent Ocular Herpes Infection and Disease. Bolstering the Number and Function of HSV-1-Specific CD8+ Effector Memory T Cells and Tissue-Resident Memory T Cells in Latently Infected trigeminal ganglia reduces recurrent ocular herpes infection and disease. Journal of Immunology. July 1;199(1):186-203, 2017. doi: 10.4049/jimmunol.700145. PMID 28539429.

McLaren CE, Chen WP, O'Sullivan TD, Gillen DL, Su MY, Chen JH, Tromberg BJ. Sample size and power determination when limited preliminary information is available. BMC Medical Research Methodolology. Apr 26;17(1):75, 2017. doi: 10.1186/s12874-017-0329-1. PMCID:PMC5406943.

Huang JY, Samarasena JB, Tsujino T, Lee J, Hu KQ, McLaren CE, Chen WP, Chang KJ.
EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. Gastrointest Endosc. 2016 Sep 29. pii: S0016-5107(16)30626-5. doi: 10.1016/j.gie.2016.09.026. [Epub ahead of print]. PMID:27693644.

Aminololama-Shakeri S, Flowers CI, McLaren CE, Wisner DJ, de Guzman J, Campbell JE, Bassett LW, Ojeda-Fournier H, Gerlach K, Hargreaves J, Elson SL, Retallack H, Joe BN, Feig SA, Wells CJ; ATHENA Breast Health Initiative. AJR Am J Roentgenol 208(4):933-939, 2017. PMID:28199152

Barton JC, Chen WP, Emond , Phatak PD, Subramaniam VN, Adams PC, Gurrin LC, Anderson GJ, Ramm GA, Powell LW, Allen KY, Phillips JD, Parker CJ, McLaren GD, McLaren CE. GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes. Blood Cells, Molecules, and Disease 63:15-20, 2017. PMID:27936396.

Warne CD, Zaloumis SG, Bertalli NA, Delatycki MB, Nicoll AJ, McLaren CE, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ and Gurrin LC. "HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: a genotype-stratified cohort study of hemochromatosis in Australian women. Journal of Gastroenterology and Hepatology 32:797–802, 2017. PMID 27784128.

Farrell CP, Overbey JR, Naik H, Nance D, McLaren GD, McLaren CE, Zhou L, Desnick RJ, Parker CJ, Phillips JD. Identification of polymorphic glyceronephosphate O-acyltransferase as a risk factor for porphyria cutanea tarda. PLoS One 11(9), 2016. DOI:10.1371/journal.pone.0163322. PMCID: PMC5035022.

Chen JH, Chan S, Tang YT, Hon JS, Tseng PC, Cheriyan AT, Shah NR, Yeh DC, Lee SK, Chen WP, McLaren CE, Su MY. Impact of positional difference on the measurement of breast density using MRI. Med Phys 42(5):2268-75, 2015. PMCID: PMC4401799.

Leproux A, Kim YM, Min JW, McLaren CE, Chen W-P, O’Sullivan T, Lee S, Chung P-S, Tromberg, BJ. Differential diagnosis of breast masses in South Korean premenopausal women using Diffuse Optical Spectroscopic Imaging (DOSI. Journal of Biomedical Optics (JBO) 21(7):74001 (1-10), 2016. PMCID: PMC4951543.

McLaren CE, Emond MJ, Subramaniam N, Phatak PD, Barton JC, Adams PC, Goh JB, McDonald CJ, Powell LW, Gurrin LC, Allen KJ, Nickerson DA, Louie T, Ramm, GA, Anderson GJ, McLaren GD. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload. Hepatology 62(2):429-439, 2015. PMCID: PMC4508230.

Zaloumis SG, Allen KJ, Bertalli NA, Turkovic L, Delatycki MB, Nicoll AJ, McLaren CE, English DR, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC; HealthIron Study Investigators. Natural history of HFE simple heterozygosity for C282Y and H63D: a prospective twelve year study. Journal of Gastroenterology and Hepatology. J Gastroenterol Hepatol 30(4):719-25, 2015. PMCID: PMC4782752.

Billheimer D, Gerner EW, McLaren CE, LaFleur B. Combined benefit of prediction and treatment : a criterion for evaluating clinical prediction models. Cancer Inform 13 (Suppl 2):93-103, 2014. PMCID: PMC4197927.

Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res 7(5):496-504, 2014. PMCID: PMC4208700.

Jia Z, Lilly MB, Koziol JA, Chen X, Xia X-Q, Wang Y, Skareky D, Suttton M, Sawyers A, Ruckle H, Carpenter PM, Want-Rodriguez J, Jjiang J, Deng M, Pan C, Zhu J-g, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D. Generation of “virtual” control groups for single arm prostate cancer adjuvant trials. PLoS ONE 9(1):e85010, 2014. doi:10.1371/journal.pone.0085010. PMCID: PMC3897405.

Mainous AG, 3rd, Wright RU, Hulihan MM, Twal WO, McLaren CE, Diaz VA, McLaren GD, Argraves S, Grant AM. Elevated transferrin saturation, health-related quality of life and telomere length. Biometals 27(1):135-41, 2014. PMCID: PMC4034347.

Chen JH, Bahri S, Mehta RS, Carpenter PM, McLaren CE, Chen WP, Fwu PT, Hsiang DJB, Lane KT, Butler JA, Su MY. Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology. J Surg Oncol 109(2):158-67, 2014. PMCID: PMC4005994.
Koh CY, Demirjian AN, Chen WP, McLaren CE, Imagawa DK. Validation of revised American joint committee on cancer staging for gallbladder cancer based on a single institution experience. Am Surg 79(10):1045-9, 2013. PMCID: PMC4017658.

Barton JC, Adams PC, Acton RT, Speechley M, McLaren CE, McLaren GD, Gordeuk VR, Eckfeldt JH. Proton pump inhibitors and lower serum ferritin levels in 171 HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Vitamin Miner. 2(2):1000112, 2013. doi: 10.4172/vms.1000112.

Chen JH, Pan WF, Kao J, Lu J, Chen LK, Kuo CC, Chang CK, Chen WP, McLaren CE, Bahri S, Mehta RS, Su MY. Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated at 3T MR. NMR Biomed 26(12): 1705-13, 2013. PMCID:3838444.

Davis BH, McLaren CE, Carcio AJ, Wong L, Hedley BD, Keeney M, Curtis A, Culp NB. Determination of optimal replicate number for validation of imprecision using fluorescence cell based assays: Proposed practical method. Cytometry B Clin Cytom 84(5):329-37, 2013.

Chen JH, Chen WP, Chan S, Yeh DC, Su MY, McLaren CE. Correlation of endogenous hormonal levels, fibroglandular tissue volume and percent density measured using 3D MRI during one menstrual cycle. Ann Oncol 24(9): 2329-35, 2013. PMCID: PMC3755325.

Mainous AG 3rd, Wright RU, Hulihan MM, Waleed T, McLaren CE, Diaz VA, McLaren GD, Argraves WS, Grant AM. Telomere length and elevated iron: The influence of phenotype and HFE genotype. AM J Hematol 88(6):492-6, 2013. PMCID: PMC3784668.

Adams PC, McLaren CE, Speechley M, McLaren GD, Barton JC, Eckfeldt JH. HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level < 1000 ?g/L. Can J Gastroenterol 27(7):390-392, 2013. PMCID: PMC3956024.

O'Sullivan TD, Leproux A, Chen JH, Bahri S, Matlock A, Roblyer D, McLaren CE, Chen WP, Cerussi AE, Su MY, Tromberg BJ. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res 15(1):R14, 2013. PMCID: PMC3672664.

Murray JA, McLachlan S, Adams PC, Eckfeldt JH, Garner CP, Vulpe CD, Gordeuk VR, Brantner T, Leiendecker-Foster C, Killeen AA, Acton RT, Barcellos LF, Nickerson DA, Beckman KB, McLaren GD, McLaren CE. Celiac disease: association with iron deficiency in Caucasians but not in non-Caucasians. Clin Gastroenterol Hepatol 11(7):808-814, 2013. PMCID: PMC3843318.

Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108(3):512-8, 2013. PMCID: PMC3593561.

Jia Z, Want Y, Hu Y, McLaren C, Yu Y, Ye K, Xia XQ, Lemhardt W. McClelland M, Mercola D. A sample selection strategy to boost the statistical power of signature detection in cancer expression profile studies. Anticancer Agents Med Chem 13(2):203-11, 2013. PMCID: PMC3786411.

Pinn-Bingham M, Puthawala AA, Syed AMN, Sharma A, DiSaia P, Berman M, Tewari KS, Randall-Whitis L, Mahmood U, Ramsinghani N, Kuo J, Chen W-P, McLaren CE. Outcomes of High-Dose-Rate Interstitial Brachytherapy in the Treatment of Locally Advanced Cervical Cancer: Long-term Results. Int J Radiat Oncol Biol Phys 85(3):714-20, 2013. PMCID: PMC3842617.

Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + Sulindac for the prevention of sporadic colorectal adenoma. Cancer Causes Control 23(10):1739-44, 2012. PMCID: PMC3343348.

McLaren CE, McLachlan S, Garner CP, Vulpe CD, Gordeuk VR, Eckfeldt JH, Adams PC, Acton RT, Murray JA, Leiendecker-Foster C, Snively BM, Barcellos LF, Cook JD, McLaren GD. Associations between single nucleotide polymorphisms in iron-related genes and iron status in multiethnic populations. PLoS One 7(6):e38339, 2012. PMCID: PMC3382217.

Adams PC, Speechley M, Barton JC, McLaren CE, McLaren GD, Eckfeldt JH. Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the HEIRS Study. Hepatology 55(6):1722-6, 2012. PMCID: PMC3355194.

Gordeuk VR, Lovato L, Barton J, Vitolins M, McLaren G, Acton R, McLaren C, Harris E, Speechley M, Eckfeldt JH, Diaz S, Sholinsky P, Adams P. Dietary iron intake and serum ferritin concentration in 213 patients homozygous for the HFE C282Y hemochromatosis mutation. Can J Gastroenterol 26(6):345-9, 2012. PMCID: PMC3378281.

Bertalli NA, Allen KJ, McLaren CE, Turkovic L, Osborne NJ, Constantine CC, Delatycki MB, English DR, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC. A comparison of self-reported and record-linked blood donation history in an Australian cohort. Transfusion 51(10):2189-98, 2011. PMID 21985049.

Carpenter PM, Chen W-P, Mendez A, McLaren CE, Su M-Y. Angiogenesis in the progression of breast ductal proliferations. Int J Surg Pathol 19(3):35-41, 2011. PMCID: PMC3771508.

Roblyer D, Ueda S, Cerussi A, Tanamai W, Durkin A, Mehta R, Hsiang D, Butler JA, McLaren C, Chen WP, Tromberg B. Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci USA 108(35):14626-31, 2011. PMCID: PMC3167535.

Mainous AG, Diaz VA, Everett CJ, Knoll ME, Hulihan MM, Grant AM, McLaren CE, McLaren GD. Iron Overload ScreeNing Tool (IRON): Development of a Tool to Guide Screening in Primary Care. Am J Hematol 86(9):733-7, 2011. PMCID: PMC3779368.
McLaren CE, Garner CP, Constantine CC, McLachlan S, Vulpe CD, Snively BM, Gordeuk VR, Nickerson DA, Cook JD, Leiendecker-Foster C, Beckman KB, Eckfeldt JH, Barcellos LF, Murray JA, Adams PC, Acton RT, Killeen AA, McLaren GD. Genome-wide association study identifies genetic loci associated with iron deficiency. PLoS One 6(3):e17390, 2011.
Garcia AM, McLaren CE, Meyskens FL, Jr. Melanoma: is hair the root of the problem? Pigment Cell Melanoma Res 24(1):110-118, 2011.
Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, Anderson GJ, Southey MC, Olynyk JK, Powell LW, Hopper JL, Giles GG, English DR. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 51(4):1311-1318, 2010.

Meyskens FL, Jr., McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst 102(24):1815-1817, 2010.

McLaren CE, Barton JC, Eckfeldt JH, McLaren GD, Acton RT, Adams PC, Henkin LF, Gordeuk VR, Vulpe CD, Harris EL, Harrison BW, Reiss JA, Snively BM. Heritability of serum iron measures in the hemochromatosis and iron overload screening (HEIRS) family study. Am J Hematol 85(2):101-105, 2010.
Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst 102(19):1513-1516, 2010.
Constantine CC, Anderson GJ, Vulpe CD, McLaren CE, Bahlo M, Yeap HL, Gertig DM, Osborne NJ, Bertalli NA, Beckman KB, Chen V, Matak P, McKie AT, Delatycki MB, Olynyk JK, English DR, Southey MC, Giles GG, Hopper JL, Allen KJ, Gurrin LC. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. Br J Haematol 147(1):140-149, 2009.
McLaren CE, Chen WP, Nie K, Su MY. Prediction of malignant breast lesions from MRI features: a comparison of artificial neural network and logistic regression techniques. Acad Radiol 16(7):842-851, 2009.
Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2(3):209-212, 2009.
McLaren CE, Gordeuk VR, Chen WP, Barton JC, Acton RT, Speechley M, Castro O, Adams PC, Snively BM, Harris EL, Reboussin DM, McLachlan GJ, Bean R. Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and Whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Translational Research 151(2):97-109, 2008.
McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Gerner E., Meyskens FL. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of DFMO and sulindac for prevention of sporadic colorectal adenomas. Cancer Prevention Research 1:514-521, 2008.
Meyskens FLM, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G., Lawson MJ, Kidao J, McCracken J, Albers C, Ahnen DJ, Turgeon DK, Goldschmidt S, Lance P, Hagedorn CH, Gillen DL, Gerner E. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled double-blind trial. Cancer Prevention Research 1:32-38, 2008.
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Giles GG, English DR. Hopper JL, Olynyk JK, Powell LW, Gertig DM. A prospective study of mutations in the HFE gene and development of hereditary hemochromtosis disease. New England Journal of Medicine 358(3):221-230, 2008.
Constantine CC, Gurrin LC, McLaren CE, Bahlo M, Anderson GJ, Vulpe CD, Forrest S, Allen KJ, Gertig DM. SNP selection for genes of iron metabolism: a study of genetic modifiers of hemochromatosis. BMC Medical Genetics 9:18, 2008.
McLaren CE, Barton JC, Gordeuk VR, Wu L, Adams PC, Reboussin DM, Speechley M, Chang H, Acton RT, Harris EL, Castro O, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Determinants and Characteristics of Mean Corpuscular Volume and Hemoglobin Concentration in White HFE C282Y Homozygotes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. American Journal of Hematology 82:808-905, 2007.
McLaren CE, Li K-T, McLaren GD, Gordeuk VR, Snively BG, Reboussin DM, Barton JC, Acton RT, Dawkins FW, Harris EL, Moses GC, and Adams PC. Mixture models of serum biochemical measures in screening for hemochromatosis and iron overload. Translational Research 148:196-206, 2006.
Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and Iron Overload Screening (HEIRS) Study: Screening of a primary care population. New England Journal of Medicine 352:1769-1778, 2005.
Carpenter PM, Linden K, McLaren CE, Li K-T, Arain S, Barr RJ, Meyskens FL. Nuclear morphometry of actinic keratosis and sun-damaged skin. Cancer Epidemiology, Biomarkers, and Prevention 13:1996-2002, 2004.
McLaren CE, Li K-T, Garner CP, Beutler E, Gordeuk, VR. Mixture Distribution analysis of phenotypic markers reflecting HFE gene mutations. Blood 102:4563-4566, 2003.
McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, Reboussin DM, McLaren GD, Sholinsky P, Walker AP, Gordeuk VR, Leiendecker-Foster C, Dawkins FW, Eckfeldt JH, Mellen BG, Speechley M, Thomson E for the Hemochromatosis and Iron Overload Study Research Investigators. Hemochromatosis and iron overload screening (HEIRS) Study Design for an Evaluation of 100,000 primary care-based adults. The American Journal of the Medical Sciences 325:53-62, 2003.
Cadez IV, Smyth P, McLachlan GJ, McLaren CE. Maximum likelihood estimation of mixture densities for binned and truncated multivariate data. Machine Learning 47:7-34, 2002.
McLaren CE, Li K-T, Gordeuk VR, Hasselblad V, McLaren GD, Looker AC. Relationship between transferrin saturation and iron stores in U.S. African-American and Caucasian Populations. Blood 98-2345-51, 2001.
McLaren CE. Ascertainment of hemochromatosis Heterozygosity. In Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. In: Eds, Barton JC, Edwards CQ, eds. Cambridge, England: Cambridge University Press; 2000:419-426.
McLaren CE, Kambour EL, McLachlan GJ, Lukaski HC, Li X, Brittenham GM,McLaren GD. Patient-specific analysis of sequential haematological data by multiple linear regression and mixture distribution modelling. Statistics in Medicine 19:83-98, 2000.
Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 339:417-23, 1999.
McLaren CE, McLachlan GJ, Halliday JW, Webb SI, Leggett BA, Jazwinska EC, Crawford DH, Gordeuk VR, McLaren GD, Powell LW. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 114:543-9, 1998.
McLaren C, Bull B, Kambour E, Westengard J, Caswell M, Emery P, Stuart J. A Statistical approach to the selection of better laboratory tests. Laboratory Hematology 3:97-102, 1997.
McLaren CE. Mixture models in haematology: a series of case studies. Statistical Methods in Medical Research 5:129-53, 1996.
McLaren CE, Gordeuk VR, Looker AC, Hasselblad V, Edwards CQ, Griffen LM, Kushner JP, Brittenham GM. Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 86:2021-7, 1995.
McLachlan J, McLaren CE, Matthews D. An Algorithm for the Likelihood Ratio Test of One versus two components in a normal mixture model fitted to grouped and truncated data. Communications in Statistics: Simulation and Computation 24(4):965-985, 1995.
McLaren CE, Legler JM, Brittenham GM. The generalized chi-square goodness-of-fit test. J Royal Stat Soc (Series D), The Statistician 43 (2):247-258, 1994.
McLaren CE. Houwen B, Koepke JA, Rowan RM, McKay PJ, Ortner BR, Bishop ML. Analysis of red blood cell volume distributions using the ICSH reference method: detection of sequential changes in distributions determined by hydrodynamic focusing. Clin Lab Haematol 15(3):173-184, 1993.
Gordeuk VR, Thuma PE, Brittenham GM, McLaren CE, Parry D, Backenstose AR, Msiska R, Holmes L, McKainley E, Vargas L, Biemba G., Olness K, Aikawa M. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. New Engl J Med 327(21):1473-1477, 1992.
McLaren CE, Wagstaff M, Brittenham GM, Jacobs A. Detection of two component mixtures of lognormal distributions in grouped doubly-truncated data. Biometrics 47(3):607-622, 1991.
McLaren CE, Brittenham GM, Hasselblad V. Statistical and graphical evaluation of erythrocyte volume distributions. Am J Physiol 252 (Heart Circ Physiol 21):H857-H866, 1987
McLaren CE, Brittenham GM, Hasselblad V. Analysis of the volume of red blood cells: application of the expectation-maximization algorithm to grouped data from the doubly-truncated lognormal distribution. Biometrics 42(1):143-158, 1986.
McLaren CE, Brittenham GM, Gordeuk VR, Hughes MA, Keating LJ. Statistical modelling of the distribution of red blood cell volumes in iron deficiency anemia using the expectation-maximization algorithm. Statistician 35(2):135-142, 1986.
NCI Subcontract 79745CBS36, "Cancer Biomedical Informatics Grid: C3D Module Adopter", (C.E. McLaren, P.I.)
NIH/NHLBI/NHGRI, Contract N01-HC-05190,“Screening for Iron Overload and Hereditary Hemochromatosis—Field Center”, (C.E. McLaren, P.I.)
Department of Veterans Affairs Grant 121F, “Prevalence of Iron Overload and Frequency of the Hemochromatosis Gene”, (G.D. McLaren, P.I.; C.E. McLaren, Co-P.I.).
National Center for Health Statistics OMB No. 0990-0115, “Statistical Modeling of the Joint Distribution of Serum Transferrin Saturation and Serum Ferritin Data from NHANES III to Predict the Probability of Hemochromatosis Heterozygosity and Homozygosity for Hemochromatosis in U.S. White Adults”, (C. E. McLaren, P.I.)
Centre Technique de Cooperation Agricole et Rurale (CTA), “IBC98 Special Sessions for Developing Country Biometricians”, (C. E. McLaren, P.I.)
NIH, P30 CA-62203, “UCI Cancer Center Support Grant”, (F. L. Meyskens, Jr., P.I.; C. E. McLaren, Director of Biostatistics Shared Resource)
NIH, Academic Enhancement Research Award, R15 HL 58203. “Statistical Basis for Hemochromatosis Screening”, (C.E. McLaren, P.I.)
Sysmex Corporation,Cooperative R&D Agreement, “Trend Analysis for Reticulocyte Maturation and Quality Control”, (C. E. McLaren, P.I.)
The American-Portuguese Biomedical Research Fund, “Longitudinal Population Studies of Families with Hemochromatosis", (C. E. McLaren, P.I.)
NIH, Fogarty International Center, “Generalized Chi-squared Test for Comparing Distributions”, (C. E. McLaren, P.I.)
Minnesota Higher Education Board, Eisenhower Mathematics and Science Education Act grant, “Project IMPACT: Integrated Math and Physical Science”, (C. E. McLaren, P.I.)
NIH, Academic Research Enhancement Award, R15 HL48349, “Sequential Analysis of Hematologic Measurements”. (C. E. McLaren, P.I)
NIH, Academic Research Enhancement Award, R15 HL42681, “Mixtures of Red Blood Cell Volume Distributions”, (C. E. McLaren, P.I.)
Wellcome Research Travel Grant, “Microcomputer Analysis of Cell Volume Distributions”, (C. E. McLaren, P.I.)
Greater Minnesota Corporation, Technology Research Grant, TG-3000, “Automated Hematology Data Analysis System”, (C. E. McLaren, P.I.)
National Science Foundation: Instructional Laboratory Improvement Grant, USE-8851944, “Instructional Computer Laboratory for Introduction to Statistics”. (C. E. McLaren, P.I.)
University of Wales College of Medicine, Blood Research Fund Grant, “Red Blood Cell Volume Distributions in Sideroblastic Anemia”. (C. E. McLaren, P.I.)
American Heart Association: Research Fellowship, “Analysis of Red Cell Volume Distributions in Anemia”, (C.E. McLaren, P.I.)
NIH Grant 1R24DK099846-01A1, “Genetic Modifiers of Iron Status in Hemochromatosis HFE C282Y Homozygotes”, (C. E. McLaren, G.D. McLaren (multi P.I.))
NIH/NHLBI Grant 1 R01 HL083328-01A1, “Iron Status: A Pathway Analysis in Multiple Ethnicities”, (C. E. McLaren, P.I)
NIH/NHLBI Grant 1 R01 HL083328-01A1, “Iron Status: A Pathway Analysis in Multiple Ethnicities”, (C. E. McLaren, P.I)
NIH Grant 2P30 CA062203, “Cancer Center Support Grant”, (C.E. McLaren, Co-I)
NIH Grant 2P30 CA062203, “Cancer Center Support Grant”, (C.E. McLaren, Co-I)
NIH/NCI Grant 1R01 CA142989, “Developing DOSI Technology for Monitoring Response of Breast Cancer Chemotherapy”, (C.E. McLaren, Co-I)
NIH Grant 1R01 EY026103-01A1, “Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease”, (C.E. McLaren, Co-I)
NIH Grant 1R01 EY026103-01A1, “Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease”, (C.E. McLaren, Co-I)
NIH/NCI Grant 5R01 EY024618-02, “Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpes”, (C.E. McLaren, Co-I)
NIH/NCI Grant 2R01 EY019896-06, “Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits”, (C.E. McLaren, Co-I)
NIH/NCI Grant 1R21CA166839-01A1,“Phase 1 bioassay-guided Trial of Lycopene and Docetaxel for Prostate Cancer”, (C.E. McLaren, Co-I)
NIH/NCI Grant 1R21CA166839-01A1,“Phase 1 bioassay-guided Trial of Lycopene and Docetaxel for Prostate Cancer”, (C.E. McLaren, Co-I)
NIH/NCI Grant 1R21CA170955-01A1,“Volume and Morphology of Fibroglandular Tissue for Breast Cancer Risk”, (C.E. McLaren, Co-I)
NIH/NCI Grant 2R01 EY014900, “Ocular Mucosal Immunity Induced by HSV-1 Lipopeptides”, (C.E. McLaren, Co-I)
NIH/NHLBI Grant 1U01DD000754-01, “Hereditary Hemochromatosis and Telomere Length”, (C.E. McLaren, Co-I)
Safeway, Corp. Subcontract 1U01DD000754-01, “Athena Breast Health Network Program: UCI Steering Committee”, (C.E. McLaren, Co-I)
NIH/NCI Grant K23CA133142, “Risk reduction through polyamine inhibition among colorectal carcinoma patients”, (C.E. McLaren, Co-I)
NIH/NCI Grant R21-R33 CA120175, “Development of a Multi-Modality System for Onco-Imaging”, (C.E. McLaren, Co-I)
NIH/NCI Grant N01-CN-35160, “Phase 1 & 2 Clinical Trials of Chemoprevention Agents”, (C.E. McLaren, Co-I, Biostatistician)
NIH/NIBIB Grant R01 EB008716, “Tomographic Molecular Imaging for Breast Cancer”, (C.E. McLaren, Co-I)
BOOZ Allen & Hamilton, Inc., Subcontract 94450NBS23, “caBIG Task Order Number: 4 (CTMS TF CM)”, (C.E. McLaren, P.I.)
Professional Societies
American Statistical Association (FELLOW, 1993), Chair, Council of Chapters Governing Board, 2004; Executive Committee, Biometrics Section, 2001-2004; Chair, Section on Statistical Education, 1999; River Valley Chapter, Chapter Representative, 1992-95, President, 1990-91, Secretary, 1989-90.
International Biometrics Society, Executive Council, 2003-2006; President-Elect, Western North American Region (WNAR), 2004; Regional Advisory Board, WNAR, 2001-2003; IBS Education Committee, 1996-1999.
Council on Undergraduate Research. Mathematical and Computer Sciences Council, Councilor, 1992-2000.
International BioIron Society
Royal Statistical Society (FELLOW, 1990)
Graduate Programs
Research Centers
Genetic Epidemiology Research Institute
Last updated